Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis

被引：0

作者：

Boluda, Juan Carlos Hernandez ^{[1
]}

Eikema, Dirk-Jan ^{[2
]}

Erazo, Nadia ^{[3
]}

Kroeger, Nicolaus ^{[4
]}

Robin, Marie ^{[5
]}

de Witte, Moniek ^{[6
]}

Finke, Juergen ^{[7
]}

Rambaldi, Alessandro ^{[8
]}

Broers, Annoek E. C. ^{[9
]}

Raida, Ludek ^{[10
,11
]}

Schaap, Nicolaas ^{[12
]}

Chiusolo, Patrizia ^{[13
]}

Verbeek, Mareike ^{[14
]}

Choi, Goda ^{[15
]}

Halaburda, Kazimierz ^{[16
]}

Kulagin, Alexander D. ^{[17
]}

Labussiere-Wallet, Helene ^{[18
]}

Gedde-Dahl, Tobias ^{[19
]}

Rabitsch, Werner ^{[20
]}

Raj, Kavita ^{[21
]}

Drozd-Sokolowska, Joanna ^{[22
]}

Polverelli, Nicola ^{[23
]}

Czerw, Tomasz ^{[24
,25
]}

Yakoub-Agha, Ibrahim ^{[26
]}

McLornan, Donal P. ^{[27
]}

机构：

[1] Hosp Clin Univ, Hematol Dept, Valencia, Spain

[2] EBMT Stat Unit, Leiden, Netherlands

[3] EBMT Leiden Study Unit, Leiden, Netherlands

[4] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

[5] Univ Paris Cite, Hop St Louis, AP HP, Paris, France

[6] UMC Utrecht, Utrecht, Netherlands

[7] Univ Freiburg, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[8] Azienda Socio Sanit Terr Papa Giovanni XXIII, Dept Oncol Hematol, Bergamo, Italy

[9] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[10] Palacky Univ Olomouc, Fac Med & Dent, Dept Hematooncol, Olomouc, Czech Republic

[11] Univ Hosp Olomouc, Olomouc, Czech Republic

[12] Radboud Univ Nijmegen, Dept Hematol, Med Ctr, Nijmegen, Netherlands

[13] Fdn Policlin Univ A Gemelli IRCCS, Dept Diagnost Immagini Radioterapia Oncol & Emato, Rome, Italy

[14] TUM, Klinikum Rechts Isar, Munich, Germany

[15] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[16] Inst Hematol & Transfus Med, Warsaw, Poland

[17] Pavlov Univ, RM Gorbacheva Res Inst, St Petersburg, Russia

[18] Ctr Hosp Lyon Sud, Hematol Dept 1 G, Pierre Benite, France

[19] Oslo Univ Hosp, Rikshosp, Hematol Dept, Clin Canc Med,Sect Stem Cell Transplantat, Oslo, Norway

[20] Med Univ Vienna, BMT Unit, Vienna Gen Hosp, Internal Med 1, Vienna, Austria

[21] Univ Coll London Hosp NHS Trust, London, England

[22] Med Univ Warsaw, Cent Clin Hosp, Warsaw, Poland

[23] Univ Brescia, Dept Clin & Expt Sci, Unit Blood Dis & Stem Cell Transplantat, ASST Spedali Civili Brescia, Brescia, Italy

[24] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland

[25] Inst Oncol, Gliwice Branch, Gliwice, Poland

[26] Univ Lille, INSERM, U1286, Ctr Hosp Univ Lille LIRIC, Lille, France

[27] Univ Coll London Hosp, Dept Haematol & Stem Cell Transplantat, London, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163048

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10608 / 10610

页数：3

共 50 条

[31] Risk factors for blood product usage following sibling allogeneic haemopoietic stem cell transplantation (allo-HCT)
Hurst, Nicola
Mullighan, Charles G.
Heatley, Sue L.
Robinson, Kathryn
Danner, Silke
Hahn, Uwe
Szer, Jeff
Shuttleworth, Peter
Hoyt, Rosie
Schwarer, Anthony P.
Muirhead, Jenny
Bradstock, Kenneth
Miller, Lisa
Bardy, Peter G.
BLOOD, 2007, 110 (11) : 856A - 856A
[32] Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
Burke, M. J.
Trotz, B.
Luo, X.
Weisdorf, D. J.
Baker, K. S.
Wagner, J. E.
Verneris, M. R.
BONE MARROW TRANSPLANTATION, 2009, 44 (03) : 169 - 174
[33] IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
Mohty, Razan
Vanegas, Yenny Moreno
Heckman, Michael G.
Alkhateeb, Hassan B.
Hochwald, Alexander P.
Hogan, William J.
Kharfan-Dabaja, Mohamed A.
Ketterling, Rhett P.
Khera, Nandita
Litzow, Mark R.
Mangaonkar, Abhishek A.
Murthy, Hemant S.
Palmer, Jeanne M.
Shah, Mithun, V
Sproat, Lisa Z.
Viswanatha, David S.
Foran, James M.
BLOOD, 2022, 140 : 4863 - 4864
[34] Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
M J Burke
B Trotz
X Luo
D J Weisdorf
K S Baker
J E Wagner
M R Verneris
Bone Marrow Transplantation, 2009, 44 : 169 - 174
[35] EXTRAMEDULLARY RELAPSE OF ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HCT): BETTER PROGNOSIS THAN SYSTEMIC RELAPSE
Solh, M.
Kaufman, D. S.
Defor, T.
Weisdorf, D. J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S156 - S156
[36] Body Composition Predicts for Survival in Allogeneic (allo) Hematopoietic Stem Cell Transplantation (HCT) Recipients
Mishra, Asmita
Pidala, Joseph A.
Betts, Brian
Fernandez, Hugo
Nishihori, Taiga
Extermann, Martine
Jim, Heather
Anasetti, Claudio
Xiong, Yin
Magliocco, Anthony
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S69 - S69
[37] Pulmonary Arterial Hypertension (PAH) Is Associated with Increased Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation (allo HCT) for Myelofibrosis
Gupta, Rohan
Jamal, Faizi
Yang, Dongyun
Ali, Haris
Aldoss, Ibrahim
Al Malki, Monzr M.
Mei, Matthew
Salhotra, Amandeep
Dobrin, Surime
Tran, Michael
Venkataraman, K.
Palmer, Joycelynne
Stein, Anthony S.
Sandhu, Karamjeet S.
Khaled, Samer K.
Aribi, Ahmed
Marcucci, Guido
Forman, Stephen J.
Snyder, David S.
Nakamura, Ryotaro
Pullarkat, Vinod
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[38] Transformed Indolent Lymphoma Outcomes Similar to De Novo Diffuse Large B-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation (AHCT), but Not Allogeneic HCT (Allo-HCT)
Pathak, Priyadarshini
Shah, Gunjan L.
Tsyvkin, Elina
Maloy, Molly
Knezevic, Andrea
Devlin, Sean M.
Giralt, Sergio A.
Matasar, Matthew J.
Moskowitz, Craig H.
Sauter, Craig S.
Perales, Miguel-Angel
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S244 - S245
[39] Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
Efebera, Yvonne A.
Geyer, Susan
Andritsos, Leslie
Vasu, Sumithira
Jaglowski, Samantha
Bingman, Anissa
Blum, William
Klisovic, Rebecca
Hofmeister, Craig C.
Benson, Don M.
Penza, Sam
Elder, Patrick
Cortright, Katie
Kitzler, Rhonda
Coombes, Kevin
O'Donnell, Lynn
Daneault, Beth
Bradbury, Hillary
Zhang, Jianying
Chen, Xilin
Garman, Sabrina
Ranganathan, Parvathi
Yu, Xueyan
Hofstetter, Jessica
Yu, Jianhua
Garzon, Ramiro
Scrape, Scott R.
Lozanski, Gerard
Devine, Steven M.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (01) : 71 - 79
[40] Analysis of post Allo-HCT relapse in acute leukaemia patients, a comparative on second Allo-HCT and donor lymphocyte infusions
Orti, G.
Sanz, J.
Garcia-Cadenas, I.
Sanchez-Ortega, I.
Jimenez, M. J.
Barba, P.
Ferra, C.
Parody, R.
Sierra, J.
Sanz, M. A.
Querol, S.
Valcarcel, D.
BONE MARROW TRANSPLANTATION, 2017, 52 : S389 - S389

← 1 2 3 4 5 →